Researchers evaluated the efficacy and safety of ixekizumab over a 16-week period for the treatment of juvenile psoriatic arthritis or enthesitis-related arthritis.

Deucravacitinib was safe and effective for treating moderate to severe scalp psoriasis over 16 weeks, even among patients with less extensive overall disease. Deucravacitinib demonstrates significant ...

After peak in 2020, significant decrease seen in firearm injury-related visit rates year over year from 2020 to 2023 ...

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks.

The Food and Drug Administration (FDA) has approved Zurnai ™, the first nalmefene HCl autoinjector for the emergency treatment of known or suspected opioid overdose in adults an ...

Researchers assessed the safety and efficacy of apremilast over a 48-week period for the treatment of early oligoarticular psoriatic arthritis.

The American Academy of Sleep Medicine published guidance regarding the treatment of restless leg syndrome and periodic limb movement disorder.

At ObesityWeek 2024, researchers presented the latest data on treatment regimens for chronic weight management, including GLP ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Ms E performed a comprehensive breast examination and did not find a lump. She did, however, note that the patient’s breasts ...

Researchers found a significant decrease in SBP and DBP in the overall group and in the high-dose group at 6 and 12 months.

This study emphasizes the importance of the age and timing of menopausal hormone therapy on the risk of cognitive decline after menopause.